FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Amgen's D-mab beats Fosamax in trial

Tools

In a head-to-head trial, Amgen's twice-yearly osteoporosis drug denosumab outperformed weekly oral doses of Merck's Fosamax. D-mab, as it's known, showed greater improvement in bone mineral density in the hip and spine compared to Fosamax. "The novel means by which denosumab inhibits osteoclast-mediated bone breakdown shows the promise of RANK Ligand inhibition," said Javier San Martin, Global Development Lead for the denosumab osteoporosis program.

- see Amgen's release
- read the report for more

Related Articles:
Merck expects $1.8B hit on Fosamax
Amgen's D-mab posts positive in late-stage trial
Amgen CEO touts blockbuster potential of D-mab
Denosumab: Amgen's salvation?
Amgen touts progress in two key programs

More stories about osteoporosis   Merck   Ligand Pharmaceuticals   Drug Trials   Clinical Trial Results   Amgen  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.